Evotec Stock: Dramatic Rebound Sparks Takeover Speculation

After a prolonged downward spiral, Evotec shares have mounted an impressive comeback, surging 15-17% to reach €8.24—their highest level since early March. This remarkable rally follows a brief dip to €6.60, where buyers emerged at the crucial 50-day moving average, triggering a potential trend reversal. The recovery offers a glimmer of hope for long-suffering shareholders who witnessed the stock plummet from €46 in September 2021 to a mere €5.06 in April this year. Market analysts, including Canada's RBC, have contributed to the positive sentiment by raising their price target to €11.90 and maintaining an "outperform" rating, citing Evotec's potential to close its margin gap with competitors over the next three years.

Undervaluation Fuels Acquisition Rumors

The biotech company's dramatic devaluation—from a market capitalization exceeding €7 billion in 2021 to approximately €1.4 billion today—has ignited speculation about a potential takeover. This undervaluation theory gained traction amid the stock's explosive performance despite no concrete company news driving the surge. Simultaneously, Evotec is executing a strategic realignment involving significant streamlining of its project portfolio. The stock's resurgence also coincides with investors seeking new opportunities beyond recently rallying sectors like defense and high-tech, potentially redirecting attention toward biotech valuations. The coming trading days will reveal whether this recovery represents a sustainable trend or merely a temporary bounce.

Ad

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld